Ongoing Clinical Trials

A Phase 2b study for patients with moderate to severe benign prostatic hyperplasia (BPH) using PRX302, was initiated in January 2009 and top-line results are expected in Q4 2009. 

In this study up to 90 patients will receive either PRX302 (3µg/ml) or placebo at a volume equivalent to 20 percent of the total prostate volume with a minimum 1.5 mL per deposit. Each dose will be delivered in three distinct deposition points along the urethra through a single ultrasound-guided transperineal injection into each lobe of the prostate. Therapeutic activity will be assessed based on symptomatic relief, prostate shrinkage and uroflow measurements at three months following a single treatment with PRX302.

For more information about this trial, please contact:

Nina Merchant
VP, Development and Regulatory Affairs
nmerchant@protoxtherapeutics.com